Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small Is Beautiful: Is ctDNA Ready for Routine Implementation in Cancer Management?

Cancers·2026
Same author

Comprehensive mapping of identical sequences across human proteins emphasizes the widespread issue of shared epitopes in self-antigens.

NAR genomics and bioinformatics·2026
Same author

Novel post-transcriptional dimension of glucocorticoid action through mRNA translation and P-body remodeling.

Signal transduction and targeted therapy·2026
Same author

A FGFR3 decoy receptor attenuates lung fibroblast-to-myofibroblast transition and pulmonary fibrosis.

American journal of respiratory cell and molecular biology·2026
Same author

Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.

Nature communications·2025
Same author

Rethinking EPO: A Paradigm Shift in Oncology?

Cancers·2025

Related Experiment Video

Updated: Jul 25, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution.

Olivia Vidal-Cruchez1,2, Victoria J Nicolini1,2, Tifenn Rete1,2

  • 1Université Côte d'Azur, Institute of Research on Cancer and Aging of Nice (IRCAN), CNRS, INSERM, Centre Antoine Lacassagne, 28, Avenue de Valombrose, 06107 Nice, France.

Cancers
|June 28, 2023
PubMed
Summary

Mitogen-activated protein kinase (MAPK) pathway inhibitors increase RAS oncogene translation by dissolving processing body (P-body) biocondensates, leading to cancer drug resistance. This reveals a new feedback loop in MAPK signaling.

Keywords:
MEK inhibitorsRAS oncogenic signalingRNA metabolismliquid–liquid phase separationtranslation regulation

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.1K

Related Experiment Videos

Last Updated: Jul 25, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.1K

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Biology

Background:

  • Mitogen-activated protein kinase (MAPK) pathway overactivation drives many human cancers.
  • Cancer drug resistance arises from therapies targeting this pathway, often linked to compensatory RAS overexpression.
  • Mechanisms underlying RAS overexpression and subsequent drug resistance remain unclear.

Purpose of the Study:

  • To investigate the mechanisms by which MEK inhibitors (MEKi) lead to cancer drug resistance.
  • To elucidate the role of RAS oncogene translation in MAPK pathway signaling and resistance.
  • To identify novel feedback loops regulating RAS protein expression and MAPK pathway activity.

Main Methods:

  • Utilized cell culture models across different cell types.
  • Administered MEK inhibitors (MEKi) and monitored KRAS and NRAS oncogene translation.
  • Investigated the role of processing body (P-body) biocondensates and their scaffold proteins.
  • Assessed the dynamic changes in P-bodies and RAS signaling upon MEKi removal and ERK reactivation.

Main Results:

  • MEK inhibitors (MEKi) increase KRAS and NRAS oncogene translation via P-body biocondensate dissolution.
  • This effect is dynamic, with P-bodies reforming and RAS signaling decreasing upon MEKi withdrawal.
  • Lower levels of P-body scaffold proteins correlate with increased RAS expression.
  • A novel feedback loop involving P-bodies in RAS translational regulation and MAPK signaling is identified.

Conclusions:

  • Dissolution of P-body biocondensates is a key mechanism driving RAS overexpression and subsequent cancer drug resistance.
  • Targeting this P-body-mediated translational control offers a potential strategy to overcome resistance to MAPK-targeted therapies.
  • This study uncovers a new layer of regulation in RAS-MAPK signaling, with implications for cancer treatment.